GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Targeting Unique Meyloid Populations to Overcome Anti-PD-1 Resistance Conferred by Specific Cancer Mutations

$194,589
Brian C Miller · Univ Of North Carolina Chapel Hill · K08 · FY2021 · CA

Liquid Biopsy Core

$194,588
Amir Goldkorn · University Of Southern California · P30 · FY2024 · CA

Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer

$194,528
Terence Marques Williams · Beckman Research Institute/City Of Hope · R01 · FY2024 · CA

Anti-tumor efficacy of novel cGAS-STING pathway agonists

$194,526
Victor Robert Defilippis · Oregon Health & Science University · R21 · FY2021 · CA

Tumor-directed immunostimulatory nanoparticles for novel 'prime-pull'cancer vaccination

$194,524
Prabhani Atukorale · University Of Massachusetts Amherst · K22 · FY2021 · CA

Tumor-directed immunostimulatory nanoparticles for novel 'prime-pull'cancer vaccination

$194,308
Prabhani Atukorale · University Of Massachusetts Amherst · K22 · FY2022 · CA

B7-H3 in Medulloblastoma: evaluating its expression and function to harness new therapeutic targets

$194,184
Allison M. Martin · Albert Einstein College Of Medicine · K08 · FY2022 · NS

B7-H3 in Medulloblastoma: evaluating its expression and function to harness new therapeutic targets

$194,184
Allison M. Martin · Albert Einstein College Of Medicine · K08 · FY2021 · NS

B7-H3 in Medulloblastoma: evaluating its expression and function to harness new therapeutic targets

$194,184
Allison M. Martin · Albert Einstein College Of Medicine · K08 · FY2020 · NS

Novel targets of treatment for NF1-mutant melanoma

$194,142
Iman Osman · New York University School Of Medicine · R21 · FY2022 · CA

Tumor-directed immunostimulatory nanoparticles for novel 'prime-pull'cancer vaccination

$194,090
Prabhani Atukorale · University Of Massachusetts Amherst · K22 · FY2023 · CA

Enhancing precision medicine for brain metastases using interpretable and integrative deep learning

$194,022
Albert Kim · Massachusetts General Hospital · K08 · FY2025 · EB

Combinatorial Approaches to Overcoming Resistance to BRAF(V600E) Targeted Thera

$193,972
David E Fisher · Massachusetts General Hospital · P01 · FY2014 · CA

Cellular responses to DNA replication stress

$193,884
Marcus Smolka · Cornell University · R01 · FY2018 · GM

Cervical cancer derived xenografts (PDX) and organoid raft cultures to evaluate pathway specific therapeutic agents.

$193,793
Nilam Sanjib Banerjee · University Of Alabama At Birmingham · R21 · FY2019 · CA

Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer

$193,780
Terence Marques Williams · Ohio State University · R01 · FY2020 · CA

Drg1: A Novel Molecular Target for Cancer Therapy

$193,563
Sloan-Kettering Institute For Cancer Res · R01 · FY2002 · CA

TARGETING ORIGINS OF REPLICATION WITH CANCER DRUGS

$193,500
Roswell Park Cancer Institute Corp · R01 · FY2002 · CA

Disconnecting CR2/CD21 from Its C3d Ligand to Ameliorate Lupus

$193,489
V Michael Holers · University Of Colorado Denver · R21 · FY2014 · AI

Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer

$193,244
Timothy An-Thy Chan · Cleveland Clinic Lerner Com-Cwru · U54 · FY2025 · CA

Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer

$193,243
Timothy An-Thy Chan · Cleveland Clinic Lerner Com-Cwru · U54 · FY2022 · CA

Identifying Therapeutic Vulnerabilities of c-MYC-driven Small Cell Lung Cancer

$193,042
Trudy Gale Oliver · University Of Utah · R21 · FY2019 · CA

Defining and targeting the immune-suppressive metabolic microenvironment of leptomeningeal melanoma metastases

$192,997
Inna Smalley · H. Lee Moffitt Cancer Ctr & Res Inst · R21 · FY2023 · CA

Airway Immune Response in Critically Ill Children-Precision Medicine in Children At Risk for Acute Respiratory Distress Syndrome

$192,672
Jocelyn Rebecca Grunwell · Emory University · K23 · FY2020 · HL

Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer

$192,653
Jonathan Maybaum · University Of Michigan At Ann Arbor · R01 · FY2015 · CA